EA200600258A1 - Триазолопиримидиновые производные в качестве ингибиторов киназы-3 гликогенсинтазы - Google Patents
Триазолопиримидиновые производные в качестве ингибиторов киназы-3 гликогенсинтазыInfo
- Publication number
- EA200600258A1 EA200600258A1 EA200600258A EA200600258A EA200600258A1 EA 200600258 A1 EA200600258 A1 EA 200600258A1 EA 200600258 A EA200600258 A EA 200600258A EA 200600258 A EA200600258 A EA 200600258A EA 200600258 A1 EA200600258 A1 EA 200600258A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- group
- optionally substituted
- nrr
- alkyl
- alkyl group
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical class BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Настоящее изобретение относится к соединению формулы (I), его N-оксиду, его фармацевтически приемлемой аддитивной соли, его четвертичному амину и его стереохимически изомерным формам, где кольцо А обозначает фенильную, пиридильную, пиримидинильную, пиридазинильную или пиразинильную группу; Rобозначает водород; арильную группу; формильную группу; Cалкилкарбонильную группу; Cалкильную группу; Cалкилоксикарбонильную группу; Cалкильную группу, замещенную формильной, Cалкилкарбонильной, Cалкилоксикарбонильной группой, Cалкилкарбонилоксигруппой; или СалкилоксиСалкилкарбонильную группу, необязательно замещенную Cалкилоксикарбонильной группой; Х обозначает прямую связь; группу -(СН)- или -(СН)-X-X-; Rобозначает Сциклоалкильную группу; фенильную группу; 4-, 5-, 6- или 7-членный моноциклический гетероцикл, содержащий по крайней мере один гетероатом, выбранный из О, S или N; бензоксазолильную группу или радикал формулы (а-1), где указанный заместитель Rнеобязательно может быть замещен; Rобозначает галоген; гидроксильную группу; необязательно замещенную Cалкильную группу; Салкенильную или Салкинильную группу, каждая из которых необязательно замещена; необязательно замещенную полигалоген-Салкильную группу; необязательно замещенную Cалкилоксигруппу; необязательно замещенную полигалоген-Салкилоксигруппу; Cалкилтиогруппу; полигалоген-Салкилтиогруппу; Cалкилоксикарбонильную группу; Cалкилкарбонилоксигруппу; Cалкилкарбонильную группу; полигалоген-Салкилкарбонильную группу; цианогруппу; карбоксильную группу; арилоксигруппу; арилтиогруппу; арилкарбонильную группу; группу NRR; С(=O)-NRR; -NR-C(=O)-R; -S(=O)-R; -NR-S(=O)-R; -NR-S(=O)-R; -S-CN; -NR-CN; Rобозначает водород, галоген; гидроксильную группу; необязательно замещенную Салкильную группу; Салкенильную или Салкинильную группу, каждая из которых необязательно замещена; полигалоген-Салкильную группу; необязательно замещенную Салкилоксигруппу; полигалоген-Салкилоксигруппу; Салкилтиогруппу; полигалоген-Салкилтиогруппу; Салкилоксикарбонильную группу; Салкилкарбонилоксигруппу; Салкилкарбонильную группу; полигалоген-Салкилкарбонильную группу; нитрогруппу; цианогруппу; карбоксильную группу; группу NRR; С(=O)-NRR; -NR-C(=O)-NRR; -NR-C(=O)-R; -S(=O)-R; -NR-S(=O)-R; -S-CN; -NR-CN; их применению, содержащим их фармацевтическим композициям и способам их получения.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0350310 | 2003-07-16 | ||
| PCT/EP2004/051455 WO2005012307A1 (en) | 2003-07-16 | 2004-07-12 | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200600258A1 true EA200600258A1 (ru) | 2006-06-30 |
| EA010109B1 EA010109B1 (ru) | 2008-06-30 |
Family
ID=34112425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200600258A EA010109B1 (ru) | 2003-07-16 | 2004-07-12 | Триазолопиримидиновые производные в качестве ингибиторов киназы-3 гликогенсинтазы |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7560458B2 (ru) |
| EP (1) | EP1658292B1 (ru) |
| JP (1) | JP2009514782A (ru) |
| KR (1) | KR20060120393A (ru) |
| CN (1) | CN100404536C (ru) |
| AP (1) | AP2006003486A0 (ru) |
| AR (1) | AR045698A1 (ru) |
| AT (1) | ATE370142T1 (ru) |
| AU (1) | AU2004260738B2 (ru) |
| BR (1) | BRPI0412596A (ru) |
| CA (1) | CA2531333A1 (ru) |
| DE (1) | DE602004008303T2 (ru) |
| DK (1) | DK1658292T3 (ru) |
| EA (1) | EA010109B1 (ru) |
| ES (1) | ES2290754T3 (ru) |
| IL (1) | IL173139A (ru) |
| JO (1) | JO2460B1 (ru) |
| MX (1) | MXPA06000540A (ru) |
| NO (1) | NO20060678L (ru) |
| NZ (1) | NZ545058A (ru) |
| PA (1) | PA8607001A1 (ru) |
| PL (1) | PL1658292T3 (ru) |
| PT (1) | PT1658292E (ru) |
| TW (1) | TW200524935A (ru) |
| WO (1) | WO2005012307A1 (ru) |
| ZA (1) | ZA200600385B (ru) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
| AP2006003486A0 (en) * | 2003-07-16 | 2006-02-28 | Janssen Pharmaceutica Nv | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors. |
| HRP20130602T1 (en) | 2003-07-30 | 2013-07-31 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| MY147449A (en) * | 2003-08-15 | 2012-12-14 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| CA2539548A1 (en) * | 2003-09-18 | 2005-03-31 | Conforma Therapeutics Corporation | Novel heterocyclic compounds as hsp90-inhibitors |
| AU2005286647A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
| AR051093A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa |
| US7919496B2 (en) | 2004-09-20 | 2011-04-05 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes |
| JP2008513515A (ja) | 2004-09-20 | 2008-05-01 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
| WO2006034279A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
| US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
| US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| BRPI0517272A (pt) * | 2004-10-29 | 2008-10-07 | Tibotec Pharm Ltd | derivados de pirimidina bicìclicos de inibição de hiv |
| WO2006076442A2 (en) * | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives |
| WO2007130075A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| AU2006282896A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| EP1991532B1 (en) | 2006-02-24 | 2017-01-11 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| US7968536B2 (en) * | 2007-06-29 | 2011-06-28 | Millennium Pharmaceuticals, Inc. | Heterocyclic compounds useful as RAF kinase inhibitors |
| TWI444379B (zh) | 2007-06-29 | 2014-07-11 | Sunesis Pharmaceuticals Inc | 有用於作為Ｒａｆ激酶抑制劑之化合物 |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2571867B1 (en) | 2010-05-21 | 2015-11-04 | Noviga Research AB | Novel pyrimidine derivatives |
| AU2012230229A1 (en) | 2011-03-24 | 2013-10-10 | Noviga Research Ab | Novel pyrimidine derivatives |
| AU2012367141B2 (en) * | 2012-01-28 | 2016-12-22 | Merck Patent Gmbh | Triazolo[4,5-d]pyrimidine derivatives |
| US20150051202A1 (en) | 2012-03-07 | 2015-02-19 | Merck Patent Gmbh | Triazolopyrazine derivatives |
| CN105026397B (zh) | 2013-03-05 | 2017-06-30 | 默克专利股份公司 | 作为抗癌剂的9‑(芳基或杂芳基)‑2‑(吡唑基、吡咯烷基或环戊基)氨基嘌呤衍生物 |
| CA2903903C (en) * | 2013-03-05 | 2021-05-04 | Merck Patent Gmbh | Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer |
| EP2994471B1 (en) | 2013-05-06 | 2017-05-17 | Merck Patent GmbH | Macrocycles as kinase inhibitors |
| EP3226861A2 (en) * | 2014-12-05 | 2017-10-11 | Centre National de la Recherche Scientifique (CNRS) | Compounds for treating cystic fibrosis |
| US11370793B2 (en) | 2015-08-27 | 2022-06-28 | Nantneuro, Llc | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
| US11203576B2 (en) * | 2016-03-11 | 2021-12-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| WO2025104079A1 (en) * | 2023-11-17 | 2025-05-22 | Helmholtz-Zentrum für Infektionsforschung GmbH | Salicylic acid and picolinic acid derivatives as inhibitors of energy coupling factor (ecf) transporters for the treatment of bacterial infections |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5962594A (ja) * | 1982-09-30 | 1984-04-10 | Ss Pharmaceut Co Ltd | ３，５―ジ置換―トリアゾロピリミジン誘導体 |
| US20020040031A1 (en) * | 2000-07-07 | 2002-04-04 | Glasky Michelle S. | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system |
| US6737085B2 (en) * | 2000-11-01 | 2004-05-18 | Tokiwa Phytochemical Co., Ltd. | Apocynum venetum extract for use as antidepressant |
| WO2002050073A1 (en) * | 2000-12-19 | 2002-06-27 | Smithkline Beecham P.L.C. | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| AP2006003486A0 (en) * | 2003-07-16 | 2006-02-28 | Janssen Pharmaceutica Nv | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors. |
-
2004
- 2004-07-12 AP AP2006003486A patent/AP2006003486A0/xx unknown
- 2004-07-12 JP JP2006519926A patent/JP2009514782A/ja not_active Withdrawn
- 2004-07-12 DK DK04766189T patent/DK1658292T3/da active
- 2004-07-12 EA EA200600258A patent/EA010109B1/ru not_active IP Right Cessation
- 2004-07-12 PL PL04766189T patent/PL1658292T3/pl unknown
- 2004-07-12 DE DE602004008303T patent/DE602004008303T2/de not_active Expired - Lifetime
- 2004-07-12 MX MXPA06000540A patent/MXPA06000540A/es active IP Right Grant
- 2004-07-12 CA CA002531333A patent/CA2531333A1/en not_active Abandoned
- 2004-07-12 JO JO200496A patent/JO2460B1/en active
- 2004-07-12 AT AT04766189T patent/ATE370142T1/de active
- 2004-07-12 PT PT04766189T patent/PT1658292E/pt unknown
- 2004-07-12 NZ NZ545058A patent/NZ545058A/en not_active IP Right Cessation
- 2004-07-12 US US10/564,844 patent/US7560458B2/en not_active Expired - Fee Related
- 2004-07-12 ES ES04766189T patent/ES2290754T3/es not_active Expired - Lifetime
- 2004-07-12 BR BRPI0412596-7A patent/BRPI0412596A/pt not_active IP Right Cessation
- 2004-07-12 WO PCT/EP2004/051455 patent/WO2005012307A1/en active IP Right Grant
- 2004-07-12 EP EP04766189A patent/EP1658292B1/en not_active Expired - Lifetime
- 2004-07-12 AU AU2004260738A patent/AU2004260738B2/en not_active Ceased
- 2004-07-12 KR KR1020057024541A patent/KR20060120393A/ko not_active Ceased
- 2004-07-12 CN CNB2004800201486A patent/CN100404536C/zh not_active Expired - Fee Related
- 2004-07-15 AR ARP040102496A patent/AR045698A1/es not_active Application Discontinuation
- 2004-07-15 TW TW093121066A patent/TW200524935A/zh unknown
- 2004-07-15 PA PA20048607001A patent/PA8607001A1/es unknown
-
2006
- 2006-01-12 IL IL173139A patent/IL173139A/en not_active IP Right Cessation
- 2006-01-13 ZA ZA200600385A patent/ZA200600385B/en unknown
- 2006-02-10 NO NO20060678A patent/NO20060678L/no not_active Application Discontinuation
-
2008
- 2008-09-16 US US12/211,361 patent/US20090036471A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW200524935A (en) | 2005-08-01 |
| KR20060120393A (ko) | 2006-11-27 |
| US20090036471A1 (en) | 2009-02-05 |
| JP2009514782A (ja) | 2009-04-09 |
| CA2531333A1 (en) | 2005-02-10 |
| US7560458B2 (en) | 2009-07-14 |
| MXPA06000540A (es) | 2006-03-30 |
| ES2290754T3 (es) | 2008-02-16 |
| CN100404536C (zh) | 2008-07-23 |
| JO2460B1 (en) | 2009-01-20 |
| AP2006003486A0 (en) | 2006-02-28 |
| IL173139A0 (en) | 2006-06-11 |
| PL1658292T3 (pl) | 2008-01-31 |
| US20060205721A1 (en) | 2006-09-14 |
| IL173139A (en) | 2010-04-29 |
| CN1823068A (zh) | 2006-08-23 |
| EA010109B1 (ru) | 2008-06-30 |
| NZ545058A (en) | 2008-05-30 |
| PT1658292E (pt) | 2007-10-25 |
| DK1658292T3 (da) | 2007-11-12 |
| AR045698A1 (es) | 2005-11-09 |
| ATE370142T1 (de) | 2007-09-15 |
| NO20060678L (no) | 2006-02-10 |
| BRPI0412596A (pt) | 2006-09-19 |
| EP1658292A1 (en) | 2006-05-24 |
| WO2005012307A1 (en) | 2005-02-10 |
| AU2004260738A1 (en) | 2005-02-10 |
| AU2004260738B2 (en) | 2009-07-16 |
| EP1658292B1 (en) | 2007-08-15 |
| PA8607001A1 (es) | 2005-05-10 |
| DE602004008303D1 (de) | 2007-09-27 |
| DE602004008303T2 (de) | 2008-05-08 |
| ZA200600385B (en) | 2007-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200600258A1 (ru) | Триазолопиримидиновые производные в качестве ингибиторов киназы-3 гликогенсинтазы | |
| EA200600257A1 (ru) | Производные триазолопиримидина в качестве ингибиторов киназы гликогенсинтазы-3 | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20231312A1 (es) | Derivados triciclicos de carboxamida como inhibidores de la prmt5 | |
| RU2353616C2 (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| RU2435771C2 (ru) | Производные спироиндолинона | |
| EA200400305A1 (ru) | 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность | |
| PE20231311A1 (es) | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos | |
| AR055630A1 (es) | Derivados de diazaspiro como antagonistas del receptor ccr8, un proceso para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades respiratorias. | |
| AR036597A1 (es) | Derivados de 1h-imidazol que tienen actividad agonista de cb1, agonista parcial de cb1 o antagonista de cb1 | |
| EA200701991A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО [1,5-a]ПИРИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| RU2013147736A (ru) | Хроменоновые соединения в качестве ингибиторов рi3-киназы для лечения рака | |
| RU2011108495A (ru) | Конденсированное гетероциклическое соединение | |
| RU2018126815A (ru) | Бициклические гидроксамовые кислоты, полезные в качестве ингибиторов активности деацетилазы гистонов млекопитающих | |
| RU2008142600A (ru) | Органическое соединение | |
| AR054790A1 (es) | Metodos para el tratamiento de disfuncion sexual | |
| CA2564629A1 (en) | Substituted phenylaminopyrimidines | |
| RU2015116749A (ru) | Антагонисты mglu2/3 для лечения аутических расстройств | |
| AR065249A1 (es) | Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales. | |
| EA201791816A1 (ru) | Ингибиторы kv1.3 и их применение в медицине | |
| RU2008133588A (ru) | ПРОИЗВОДНЫЕ 6-ФЕНИЛ-1Н-ИМИДАЗО[4,5-с]ПИРИДИН-4-КАРБОНИТРИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ КАТЕПСИНА К И S | |
| AR046793A1 (es) | Derivados de pirazol, antagonistas del receptor de la orexina | |
| NZ599553A (en) | Ethynyl derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |